Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a report issued on Monday. They presently have a $24.50 price objective on the biotechnology company’s stock. Chardan Capital’s price target suggests a potential upside of 49.57% from the stock’s previous close.
A number of other research firms have also recently issued reports on ARWR. William Blair reaffirmed an “outperform” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 17th. Cantor Fitzgerald set a $24.00 price target on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 11th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Arrowhead Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $21.36.
Shares of NASDAQ ARWR traded up $0.72 during midday trading on Monday, reaching $16.38. 39,081 shares of the company’s stock traded hands, compared to its average volume of 1,510,907. Arrowhead Pharmaceuticals has a one year low of $4.77 and a one year high of $22.39. The company has a market cap of $1.45 billion, a PE ratio of -25.15 and a beta of 2.23.
In related news, COO Bruce D. Given sold 42,666 shares of the firm’s stock in a transaction on Monday, January 14th. The shares were sold at an average price of $14.40, for a total transaction of $614,390.40. Following the completion of the transaction, the chief operating officer now owns 1,110,022 shares of the company’s stock, valued at $15,984,316.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $11.98, for a total transaction of $239,600.00. Following the transaction, the chief operating officer now directly owns 1,118,356 shares of the company’s stock, valued at approximately $13,397,904.88. The disclosure for this sale can be found here. In the last three months, insiders have sold 683,374 shares of company stock valued at $9,539,991. 4.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $52,000. Stratos Wealth Partners LTD. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter valued at $123,000. Wealth Architects LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $124,000. Beaumont Financial Partners LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $124,000. Finally, Meeder Asset Management Inc. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter valued at $129,000. Institutional investors own 59.52% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
See Also: How liquidity affects the bid-ask spread
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.